Literature DB >> 18593902

15-Hydroxyprostaglandin dehydrogenase is a target of hepatocyte nuclear factor 3beta and a tumor suppressor in lung cancer.

Guosheng Huang1, Rosana Eisenberg, Min Yan, Stefano Monti, Earl Lawrence, Pingfu Fu, Jaclyn Walbroehl, Ester Löwenberg, Todd Golub, Jaime Merchan, Daniel G Tenen, Sanford D Markowitz, Balazs Halmos.   

Abstract

The forkhead transcription factor hepatocyte nuclear factor 3beta (HNF3beta) is essential in foregut development and the regulation of lung-specific genes. HNF3beta expression leads to growth arrest and apoptosis in lung cancer cells and HNF3beta is a candidate tumor suppressor in lung cancer. In a transcriptional profiling study using a conditional cell line system, we now identify 15-PGDH as one of the major genes induced by HNF3beta expression. 15-PGDH is a critical metabolic enzyme of proliferative prostaglandins, an antagonist to cyclooxygenase-2 and a tumor suppressor in colon cancer. We confirmed the regulation of 15-PGDH expression by HNF3beta in a number of systems and showed direct binding of HNF3beta to 15-PGDH promoter elements. Western blotting of lung cancer cell lines and immunohistochemical examination of human lung cancer tissues found loss of 15-PGDH expression in approximately 65% of lung cancers. Further studies using in vitro cell-based assays and in vivo xenograft tumorigenesis assays showed a lack of in vitro but significant in vivo tumor suppressor activity of 15-PGDH via an antiangiogenic mechanism analogous to its role in colon cancer. In summary, we identify 15-PGDH as a direct downstream effector of HNF3beta and show that 15-PGDH acts as a tumor suppressor in lung cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18593902      PMCID: PMC2762106          DOI: 10.1158/0008-5472.CAN-07-6575

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  35 in total

1.  Cyclooxygenase 2-derived prostaglandin E2 regulates the angiogenic switch.

Authors:  Dingzhi Wang; Raymond N DuBois
Journal:  Proc Natl Acad Sci U S A       Date:  2004-01-05       Impact factor: 11.205

2.  Exploration, normalization, and summaries of high density oligonucleotide array probe level data.

Authors:  Rafael A Irizarry; Bridget Hobbs; Francois Collin; Yasmin D Beazer-Barclay; Kristen J Antonellis; Uwe Scherf; Terence P Speed
Journal:  Biostatistics       Date:  2003-04       Impact factor: 5.899

3.  Finishing the euchromatic sequence of the human genome.

Authors: 
Journal:  Nature       Date:  2004-10-21       Impact factor: 49.962

4.  Genomic structure and transcriptional regulation of the human NAD+-dependent 15-hydroxyprostaglandin dehydrogenase gene.

Authors:  A Nandy; S Jenatschke; B Hartung; K Milde-Langosch; A-M Bamberger; B Gellersen
Journal:  J Mol Endocrinol       Date:  2003-08       Impact factor: 5.098

5.  Bacterial expression and site-directed mutagenesis of two critical residues (tyrosine-151 and lysine-155) of human placental NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase.

Authors:  C M Ensor; H H Tai
Journal:  Biochim Biophys Acta       Date:  1994-09-21

6.  Insulin regulates the activity of forkhead transcription factor Hnf-3beta/Foxa-2 by Akt-mediated phosphorylation and nuclear/cytosolic localization.

Authors:  Christian Wolfrum; Daniel Besser; Edlira Luca; Markus Stoffel
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-19       Impact factor: 11.205

7.  A transcriptional profiling study of CCAAT/enhancer binding protein targets identifies hepatocyte nuclear factor 3 beta as a novel tumor suppressor in lung cancer.

Authors:  Balazs Halmos; Daniela S Bassères; Stefano Monti; Francesco D'Aló; Tajhal Dayaram; Katalin Ferenczi; Bas J Wouters; Claudia S Huettner; Todd R Golub; Daniel G Tenen
Journal:  Cancer Res       Date:  2004-06-15       Impact factor: 12.701

Review 8.  COX-2 inhibition and lung cancer.

Authors:  Alan B Sandler; Steven M Dubinett
Journal:  Semin Oncol       Date:  2004-04       Impact factor: 4.929

9.  Bioconductor: open software development for computational biology and bioinformatics.

Authors:  Robert C Gentleman; Vincent J Carey; Douglas M Bates; Ben Bolstad; Marcel Dettling; Sandrine Dudoit; Byron Ellis; Laurent Gautier; Yongchao Ge; Jeff Gentry; Kurt Hornik; Torsten Hothorn; Wolfgang Huber; Stefano Iacus; Rafael Irizarry; Friedrich Leisch; Cheng Li; Martin Maechler; Anthony J Rossini; Gunther Sawitzki; Colin Smith; Gordon Smyth; Luke Tierney; Jean Y H Yang; Jianhua Zhang
Journal:  Genome Biol       Date:  2004-09-15       Impact factor: 13.583

Review 10.  Cyclooxygenase as a target in lung cancer.

Authors:  Joanne R Brown; Raymond N DuBois
Journal:  Clin Cancer Res       Date:  2004-06-15       Impact factor: 12.531

View more
  17 in total

Review 1.  MicroRNA and AU-rich element regulation of prostaglandin synthesis.

Authors:  Ashleigh E Moore; Lisa E Young; Dan A Dixon
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

2.  Arachidonic acid pathway members PLA2G7, HPGD, EPHX2, and CYP4F8 identified as putative novel therapeutic targets in prostate cancer.

Authors:  Paula Vainio; Santosh Gupta; Kirsi Ketola; Tuomas Mirtti; John-Patrick Mpindi; Pekka Kohonen; Vidal Fey; Merja Perälä; Frank Smit; Gerald Verhaegh; Jack Schalken; Kalle A Alanen; Olli Kallioniemi; Kristiina Iljin
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

3.  Frequent downregulation of the transcription factor Foxa2 in lung cancer through epigenetic silencing.

Authors:  Daniela S Basseres; Francesco D'Alò; Beow Y Yeap; Ester C Löwenberg; David A Gonzalez; Hiroyuki Yasuda; Tajhal Dayaram; Olivier N Kocher; John J Godleski; William G Richards; Matthew Meyerson; Susumu Kobayashi; Daniel G Tenen; Balázs Halmos; Daniel B Costa
Journal:  Lung Cancer       Date:  2012-02-16       Impact factor: 5.705

4.  Combined histone deacetylase and cyclooxygenase inhibition achieves enhanced antiangiogenic effects in lung cancer cells.

Authors:  Xiaoqi Wang; Guangyuan Li; Antai Wang; Zhenfeng Zhang; Jaime R Merchan; Balazs Halmos
Journal:  Mol Carcinog       Date:  2011-11-28       Impact factor: 4.784

5.  Human Hepatocyte Nuclear Factor 4-α Encodes Isoforms with Distinct Transcriptional Functions.

Authors:  Élie Lambert; Jean-Philippe Babeu; Joël Simoneau; Jennifer Raisch; Laurie Lavergne; Dominique Lévesque; Émilie Jolibois; Mariano Avino; Michelle S Scott; François Boudreau; Francois-Michel Boisvert
Journal:  Mol Cell Proteomics       Date:  2020-03-02       Impact factor: 5.911

6.  15-PGDH is reduced and induces apoptosis and cell cycle arrest in gastric carcinoma.

Authors:  Li-Hong Lou; Da-Dao Jing; Yue-Xing Lai; Ying-Ying Lu; Ji-Kun Li; Kai Wu
Journal:  World J Gastroenterol       Date:  2012-03-14       Impact factor: 5.742

7.  15-hydroxyprostaglandin dehydrogenase-derived 15-keto-prostaglandin E2 inhibits cholangiocarcinoma cell growth through interaction with peroxisome proliferator-activated receptor-γ, SMAD2/3, and TAP63 proteins.

Authors:  Dongdong Lu; Chang Han; Tong Wu
Journal:  J Biol Chem       Date:  2013-05-16       Impact factor: 5.157

Review 8.  Targeting the eicosanoid pathway in non-small-cell lung cancer.

Authors:  Leora Horn; Michael Backlund; David H Johnson
Journal:  Expert Opin Ther Targets       Date:  2009-05-02       Impact factor: 6.902

9.  Loss of 15-hydroxyprostaglandin dehydrogenase expression contributes to bladder cancer progression.

Authors:  Stephanie Tseng-Rogenski; Jason Gee; Kathleen Woods Ignatoski; Lakshmi P Kunju; Amanda Bucheit; Hallie J Kintner; David Morris; Christopher Tallman; Joshua Evron; Christopher G Wood; H Barton Grossman; Cheryl T Lee; Monica Liebert
Journal:  Am J Pathol       Date:  2010-01-21       Impact factor: 4.307

10.  15-PGDH expression as a predictive factor response to neoadjuvant chemotherapy in advanced gastric cancer.

Authors:  Min Hu; Kai Li; Ninu Maskey; Zhigao Xu; ChunWei Peng; Sufang Tian; Yan Li; Guifang Yang
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.